Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia

Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia

Abstract Background Despite the impressive complete remission (CR) induced by CD19 CAR-T cell therapy in B-ALL, the high rate of complete responses is sometimes limited by the emergence of CD19-negative leukemia. Bispecific CAR-modified T cells targeting both CD19 and CD22 may overcome the limitatio...

Full description

Bibliographic Details
Main Authors: Hanren Dai, Zhiqiang Wu, Hejin Jia, Chuan Tong, Yelei Guo, Dongdong Ti, Xiao Han, Yang Liu, Wenying Zhang, Chunmeng Wang, Yajing Zhang, Meixia Chen, Qingming Yang, Yao Wang, Weidong Han
Format: Article
Language:English
Published: BMC 2020-04-01
Series:Journal of Hematology & Oncology
Subjects:
Bispecific
CAR
CD19
CD22
B-ALL
Immunotherapy
Online Access:http://link.springer.com/article/10.1186/s13045-020-00856-8

Internet

http://link.springer.com/article/10.1186/s13045-020-00856-8

Similar Items